In conclusion, our data implies that miR-34c-5p could be a promising strategy in the treatment of ovarian cancer via downregulation of the AREG-EGFR-ERK pathway to inhibit ovarian cancer stemness and drug resistance. This evidence concerns the gene AREG and ovarian carcinoma.